NASDAQ:CPRX
Catalyst Pharmaceuticals Stock News
$15.06
-0.270 (-1.76%)
At Close: Jun 14, 2024
Catalyst Pharmaceutical (CPRX) Gains As Market Dips: What You Should Know
10:50pm, Monday, 30'th Jan 2023 Zacks Investment Research
Catalyst Pharmaceutical (CPRX) closed the most recent trading day at $15.72, moving +1.29% from the previous trading session.
Catalyst Pharmaceuticals: The Firdapse Complexity Does Not End
06:21pm, Monday, 30'th Jan 2023
Catalyst Pharmaceuticals, Inc. has been hit with an ANDA notice from Teva Pharmaceutical Industries Limited. Firdapse, at the heart of the ANDA, has had problems before.
3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence
12:26pm, Monday, 30'th Jan 2023 Zacks Investment Research
World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
3 Momentum Anomaly Stocks to Buy as Q4 GDP Instills Confidence
09:02am, Monday, 30'th Jan 2023
World Wrestling Entertainment (WWE), Dycom (DY) and Catalyst Pharmaceuticals (CPRX) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Biotech Stocks Reward Shareholders Who Handle The Bumpy Ride
02:56pm, Friday, 27'th Jan 2023
Biotech and medical device stocks can be highly profitable. One of these volatile issues just catapulted over 41%.
Zacks.com featured highlights include Lamb Weston, Pinduoduo and Catalyst Pharmaceuticals
12:14pm, Friday, 27'th Jan 2023 Zacks Investment Research
Lamb Weston, Pinduoduo and Catalyst Pharmaceuticals are part of the Zacks Screen of the Week article.
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
02:22pm, Thursday, 26'th Jan 2023 The Motley Fool
Things aren't as bad as they might seem.
3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio
11:30am, Thursday, 26'th Jan 2023 Zacks Investment Research
Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
09:22am, Thursday, 26'th Jan 2023
Things aren't as bad as they might seem.
3 Top-Rated Profitable Stocks to Buy Using Net Income Ratio
07:32am, Thursday, 26'th Jan 2023
Lamb Weston (LW), Pinduoduo (PDD), and Catalyst Pharmaceuticals (CPRX) have been selected as the top picks with a high net income ratio.
Biotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & More
03:53pm, Wednesday, 25'th Jan 2023 Zacks Investment Research
Updates from bluebird (BLUE) and Catalyst Pharmaceuticals (CPRX) are the key highlights from the biotech sector during the past week.
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
01:03pm, Wednesday, 25'th Jan 2023 GlobeNewswire Inc.
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
07:54am, Wednesday, 25'th Jan 2023 Zacks Investment Research
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Strength Seen in Catalyst (CPRX): Can Its 9.2% Jump Turn into More Strength?
04:31am, Wednesday, 25'th Jan 2023
Catalyst (CPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Catalyst (CPRX) Down on TEVA's FDA Filing for Firdapse Generic
05:26pm, Tuesday, 24'th Jan 2023 Zacks Investment Research
Catalyst Pharmaceuticals (CPRX) receives a notice letter stating that Teva Pharmaceuticals has filed an application to the FDA seeking approval for a generic version of Firdapse.
